Saturday 17 October 2026
Export CLDX’s income statement to Excel — free account
Celldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.8%, EPS fell 10.6% and free cash flow fell 35.5%, each against the same quarter a year earlier.
27.53
1.40
−4.84%
Follow CLDX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 4 | 2 | 5 | 4 | 2 | 3 | 4 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
54.01 | 29.46 | 3.28 | 9.05 | 70.00 | 356.16 | 863.16 | 284.44 | 231.80 | 663.24 |
Altman Z-Score |
(1.42) | (1.63) | (10.64) | (11.78) | 5.48 | 36.42 | 42.22 | 27.37 | 19.06 | 14.41 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(3.34) | (5.42) | (19.14) | (23.53) | (3.23) | 13.85 | 4.67 | 5.99 | 15.11 | 1.90 |
Beneish M-Score |
(0.41) | (1.85) | (4.04) | (3.41) | (2.14) | (3.90) | (0.55) | 0.26 | (3.18) | 6.76 |
P/Operating CF |
(18.01) | (19.23) | (2.03) | (2.94) | (99.65) | (114.06) | (93.49) | (60.18) | (50.11) | (28.21) |
P/B ratio |
1.38 | 1.59 | 0.25 | 0.34 | 2.48 | 3.95 | 6.24 | 4.56 | 2.18 | 3.42 |
Price to Tangible BV |
3.94 | 4.82 | 0.42 | 0.71 | 2.91 | 4.22 | 6.80 | 4.87 | 2.26 | 3.61 |
EV/Sales |
26.76 | 19.03 | (6.10) | (7.94) | 44.26 | 269.04 | 734.75 | 223.67 | 128.81 | 473.52 |
EV/EBITDA |
0.00 | 0.00 | 0.93 | 0.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.61) | (2.43) | 0.77 | 0.61 | (8.13) | (20.54) | (16.69) | (14.35) | (5.73) | (6.11) |
EV/FCF |
(1.57) | (2.38) | 0.77 | 0.60 | (7.84) | (20.14) | (16.42) | (14.11) | (5.66) | (6.03) |
Quick Ratio |
5.44 | 5.09 | 7.71 | 5.62 | 13.81 | 24.71 | 16.41 | 13.69 | 18.38 | 10.21 |
Current Ratio |
5.55 | 5.22 | 7.86 | 5.73 | 13.93 | 24.86 | 17.07 | 13.87 | 18.91 | 10.49 |
Net Debt/EBITDA |
1.45 | 1.14 | 1.43 | 1.18 | 4.53 | 5.97 | 2.72 | 2.66 | 3.49 | 1.78 |
Debt/Assets |
1.26% | 2.08% | 2.90% | 2.97% | 1.48% | 0.68% | 0.41% | 0.86% | 0.12% | 0.21% |
Debt/Equity |
0.02 | 0.03 | 0.04 | 0.04 | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.04 | 0.04 | 0.03 | 0.04 | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
Operating CF/Net income |
0.88 | 1.07 | 0.50 | 0.91 | 0.68 | 0.86 | 0.92 | 0.76 | 1.00 | 0.82 |
Capex/Depreciation |
(0.55) | (0.36) | 0.00 | (0.19) | (0.07) | (0.36) | (0.47) | 0.57 | 0.15 | 1.10 |
| (46.27%) | (37.08%) | (83.89%) | (46.66%) | (39.41%) | (22.43%) | (30.13%) | (37.45%) | (26.84%) | (40.62%) | |
| (35.66%) | (26.62%) | (64.14%) | (36.51%) | (33.32%) | (20.72%) | (28.17%) | (34.56%) | (25.10%) | (37.63%) | |
ROIC |
(103.22%) | (73.38%) | (282.87%) | (103.29%) | (215.01%) | (312.08%) | (317.32%) | (1,010.24%) | (537.91%) | (1,828.59%) |
Return on Tangible Assets |
(74.06%) | (73.03%) | (163.29%) | (86.11%) | (31.89%) | (17.72%) | (37.09%) | (34.95%) | (22.17%) | (52.91%) |
Average Days of Receivables |
95.96 | 53.85 | 121.00 | 103.69 | 88.67 | 13.50 | 53.74 | 139.36 | 36.40 | 476.04 |
Research and Development Expense of Revenue |
1,513.79% | 754.70% | 696.68% | 1,194.29% | 573.39% | 1,146.23% | 3,489.94% | 1,714.53% | 2,329.77% | 15,862.39% |
Selling, General and Administrative Expense of Revenue |
530.19% | 196.21% | 202.02% | 431.74% | 194.88% | 440.51% | 1,153.80% | 449.14% | 549.12% | 2,837.41% |
Intangible Assets out of Total Assets |
0.45 | 0.50 | 0.31 | 0.40 | 0.13 | 0.06 | 0.08 | 0.06 | 0.03 | 0.05 |
Share Based Compensation of Revenue |
225.71% | 96.62% | 84.72% | 127.37% | 52.78% | 192.50% | 662.32% | 347.09% | 487.78% | 2,344.14% |
Graham Net Nets |
0.21 | 0.17 | 2.15 | 1.17 | 0.33 | 0.23 | 0.14 | 0.20 | 0.43 | 0.27 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(34.89%) | (25.33%) | (521.76%) | (162.78%) | (12.21%) | (4.24%) | (5.51%) | (7.20%) | (9.70%) | (14.32%) |
Free Cash Flow Yield |
(31.59%) | (27.10%) | (241.67%) | (145.67%) | (8.07%) | (3.75%) | (5.19%) | (5.57%) | (9.81%) | (11.84%) |
Revenue per Share |
1.00 | 1.49 | 0.91 | 0.25 | 0.25 | 0.11 | 0.05 | 0.14 | 0.11 | 0.02 |
Operating CF per Share |
(16.70) | (11.66) | (7.20) | (3.20) | (1.36) | (1.42) | (2.21) | (2.21) | (2.45) | (3.18) |
Capex per Share |
(0.41) | (0.21) | (0.05) | (0.05) | (0.05) | (0.03) | (0.04) | (0.04) | (0.03) | (0.04) |
Free Cash Flow per Share |
(17.11) | (11.87) | (7.25) | (3.25) | (1.41) | (1.45) | (2.25) | (2.25) | (2.48) | (3.22) |
Cash per Share |
28.04 | 16.27 | 9.00 | 4.44 | 6.56 | 9.52 | 6.50 | 8.74 | 11.26 | 7.81 |
Shareholders Equity per Share |
39.21 | 27.58 | 11.88 | 6.48 | 7.06 | 9.78 | 6.96 | 8.86 | 11.60 | 7.94 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
39.21 | 27.58 | 11.88 | 6.48 | 7.06 | 9.78 | 6.96 | 8.86 | 11.60 | 7.94 |
Free Cash Flow |
(115.79) | (101.72) | (75.71) | (47.13) | (41.90) | (62.13) | (105.49) | (109.11) | (159.70) | (213.66) |
Working Capital |
160.35 | 117.02 | 86.48 | 55.06 | 183.64 | 394.31 | 299.08 | 400.57 | 707.66 | 483.67 |
Capital Expenditures |
(2.75) | (1.79) | (0.47) | (0.71) | (1.50) | (1.22) | (1.76) | (1.82) | (1.92) | (2.71) |
Net Current Asset Value |
77.64 | 65.50 | 67.33 | 37.79 | 171.36 | 385.66 | 291.16 | 395.24 | 701.82 | 478.85 |
EV/EBIT |
0.00 | 0.00 | 0.37 | 0.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.41 | 0.14 | 0.05 | 0.20 | 0.20 | 0.26 | 0.75 | 0.26 | 0.27 | 1.76 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.38 | 0.48 | 15.34 | 0.92 | 5.56 | 0.95 | 1.00 | (0.79) | (2.89) | (0.46) |
Cash ROIC |
(25.17%) | (26.60%) | (34.01%) | (29.08%) | (10.29%) | (7.48%) | (16.68%) | (12.74%) | (10.84%) | (20.41%) |
Accounts Receivable Turnover |
4.93 | 6.96 | 3.78 | 1.71 | 5.27 | 4.71 | 9.08 | 4.63 | 4.22 | 1.14 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
1.38 | 1.83 | 2.52 | 2.09 | 1.41 | 0.99 | 0.26 | 1.49 | 1.66 | 1.36 |
Average Payables |
1.62 | 1.73 | 1.39 | 1.12 | 1.11 | 1.14 | 2.28 | 3.42 | 3.38 | 2.22 |
Average Assets |
360.47 | 349.49 | 235.72 | 139.37 | 179.39 | 340.25 | 398.69 | 409.18 | 628.98 | 687.66 |
Average Common Equity |
277.77 | 250.90 | 180.21 | 109.04 | 151.69 | 314.42 | 372.84 | 377.69 | 588.09 | 637.08 |
Columns are period end dates